EI
TCRT icon

EAM Investors’s Alaunos Therapeutics TCRT Stock Holding History

EAM Investors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,031
Closed -$782K – 342
2022
Q3 		$782K Buy
+3,031
New +$880K 0.17% 239
2015
Q3 		– Sell
-1,881
Closed -$3.39M – 336
2015
Q2 		$3.39M Buy
1,881
+1,166
+163% +$1.81M 0.4% 91
2015
Q1 		$1.16M Buy
+715
New +$1.06M 0.13% 288

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

EAM Investors's TCRT Position: Q4 2022 in Review

EAM Investors sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 3,031 shares — an estimated $782K sold.

EAM Investors first reported a position in TCRT in Q1 2015 and held it in 3 quarters. The position peaked at $3.39M in Q2 2015. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • EAM Investors reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • EAM Investors sold 3,031 Alaunos Therapeutics shares in Q4 2022, an estimated $782K.
  • EAM Investors first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 3 quarters.
  • EAM Investors's Alaunos Therapeutics position peaked at $3.39M in Q2 2015.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on EAM Investors's 13F filing for Q4 2022, filed 14 Feb 2023.